Liminatus Pharma (LIMN) Stock Forecast: StockMap's 2-Week Call

LIMN stock forecast: StockMap's model calls Liminatus Pharma Strong Underperform for the two weeks after the Nov 13 close: it expects LIMN to trail the growth index. It is a call on the gap, not a price target. Right in 4 of 6 two-week windows on LIMN since Aug 21; by chance, a call on the same dates was right 62% of the time.

Liminatus Pharma last closed at $2.99, +7.94% on the session.

Against the IVW growth benchmark the position is +8.85% over the forecast window.

Liminatus Pharma's market cap is $4.02M as of November 13, 2026.

Calls down ↘: the model's call · the next 2 weeks, vs S&P 500 growth. The lean on a scale from −100 to +100 is -69 (behind).

Where LIMN sits: sized by market cap, coloured by the day's move.

The read is built from 12 underlying insights — 1 bullish and 11 bearish.

Agreement across those insights is 92%.

45 daily calls for LIMN so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks Liminatus Pharma in the 98th percentile on return on equity, where 100 is best.

Liminatus Pharma is classified under Health Care / Biotechnology.

StockMap tracks Liminatus Pharma as the 376th largest of the 391 companies it covers in the Biotechnology industry, part of the Health Care sector.

Across that group the current two-week reads are 186 Moderate Underperform, 157 Neutral, 33 Strong Underperform and 15 Moderate Outperform.

On that composite Liminatus Pharma ranks 384th of 391 in the group, against a group median of -0.24.

Other Health Care stocks

Research and education, not investment advice. The calls on this page come from StockMap's automated model, run on the close of November 13, 2026, and are the same for every reader. Calls are graded in public, misses included: how calls are graded, and the record. Who makes the calls and who pays for the site: Disclosures.

Liminatus Pharma (LIMN) — StockMap 2-week forecast & tracked accuracy